|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|
LMFA04010083
|
ent-13-epi-13-F4t-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,2S,3S,5R)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010124
|
ent-13-epi-20-F4c-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2R,3S,5R)-3,5-dihydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010125
|
ent-13-epi-20-F4t-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2S,3S,5R)-3,5-dihydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010094
|
ent-14-F4c-NeuroP
|
(Z)-6-((1S,2R,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010091
|
ent-14-F4t-NeuroP
|
(Z)-6-((1R,2S,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010098
|
ent-14-epi-14-F4t-NeuroP
|
(Z)-6-((1S,2R,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010095
|
ent-14-epi-14-F4t-NeuroP
|
(Z)-6-((1R,2S,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010076
|
ent-16-epi-13-F4c-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,2R,3S,5R)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010077
|
ent-16-epi-13-F4t-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,2S,3S,5R)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010110
|
ent-17-F4c-NeuroP
|
(4Z,7Z)-9-((1S,2R,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010107
|
ent-17-F4t-NeuroP
|
(4Z,7Z)-9-((1R,2S,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010114
|
ent-17-epi-17-F4t-NeuroP
|
(4Z,7Z)-9-((1S,2R,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010111
|
ent-17-epi-17-F4t-NeuroP
|
(4Z,7Z)-9-((1R,2S,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010126
|
ent-20-F4c-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,3S,5R)-3,5-dihydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010123
|
ent-20-F4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,3S,5R)-3,5-dihydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010127
|
ent-20-epi-20-F4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,3S,5R)-3,5-dihydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010130
|
ent-20-epi-20-F4t-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,3S,5R)-3,5-dihydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010068
|
ent-4,11-diepi-4-Fc-NeuroP
|
3-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010069
|
ent-4,11-diepi-4-Ft-NeuroP
|
3-((1S,2S,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010020
|
ent-4,7-diepi-4-Fc-NeuroP
|
(S,E)-6-((1R,2R,3S,5R)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010021
|
ent-4,7-diepi-4-Ft-NeuroP
|
(S,E)-6-((1S,2S,3S,5R)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010014
|
ent-4-F4c-NeuroP
|
(R,E)-6-((1S,2R,3S,5R)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010011
|
ent-4-F4t-NeuroP
|
(R,E)-6-((1R,2S,3S,5R)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010060
|
ent-4-epi-11-F4c-NeuroP
|
3-((1R,2R,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010061
|
ent-4-epi-11-F4t-NeuroP
|
3-((1S,2S,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010022
|
ent-4-epi-4-Fc-NeuroP
|
(S,E)-6-((1S,2R,3S,5R)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010019
|
ent-4-epi-4-Ft-NeuroP
|
(S,E)-6-((1R,2S,3S,5R)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010036
|
ent-7,10-diepi-4-Fc-NeuroP
|
(S,4Z,8E)-9-((1R,2R,3S,5R)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010037
|
ent-7,10-diepi-4-Ft-NeuroP
|
(S,4Z,8E)-9-((1S,2S,3S,5R)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010096
|
ent-7,14-diepi-14-F4c-NeuroP
|
(Z)-6-((1R,2R,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010097
|
ent-7,14-diepi-14-F4t-NeuroP
|
(Z)-6-((1S,2S,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010030
|
ent-7-F4c-NeuroP
|
(R,4Z,8E)-9-((1S,2R,3S,5R)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010027
|
ent-7-F4t-NeuroP
|
(R,4Z,8E)-9-((1R,2S,3S,5R)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010092
|
ent-7-epi-14-F4c-NeuroP
|
(Z)-6-((1R,2R,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010093
|
ent-7-epi-14-F4t-NeuroP
|
(Z)-6-((1S,2S,3S,5R)-3,5-dihydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010012
|
ent-7-epi-4-F4c-NeuroP
|
(R,E)-6-((1R,2R,3S,5R)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010013
|
ent-7-epi-4-F4t-NeuroP
|
(R,E)-6-((1S,2S,3S,5R)-3,5-dihydroxy-2-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopentyl)-4-hydroxyhex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010038
|
ent-7-epi-4-Fc-NeuroP
|
(S,4Z,8E)-9-((1S,2R,3S,5R)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010035
|
ent-7-epi-4-Ft-NeuroP
|
(S,4Z,8E)-9-((1R,2S,3S,5R)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|